{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TBL+12&page=11",
    "query": {
      "intervention": "TBL 12",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 1228,
    "total_pages": 123,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TBL+12&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TBL+12&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T06:25:23.777Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02073656",
      "title": "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus",
        "HIV"
      ],
      "interventions": [
        {
          "name": "LDV/SOF",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 335,
      "start_date": "2014-02",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-11-03T06:25:23.777Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02073656"
    },
    {
      "nct_id": "NCT01730053",
      "title": "Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 305,
      "start_date": "2012-11-30",
      "completion_date": "2014-05-31",
      "has_results": true,
      "last_update_posted_date": "2020-04-07",
      "last_synced_at": "2026-11-03T06:25:23.777Z",
      "location_count": 54,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01730053"
    },
    {
      "nct_id": "NCT07218575",
      "title": "Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Cowden's Disease",
        "Cowden's Syndrome",
        "Lhermitte-Duclos Disease",
        "Cerebellum Dysplastic Gangliocytoma",
        "Bannayan Zonana Syndrome",
        "Myhre Riley Smith Syndrome",
        "Riley Smith Syndrome",
        "PTEN Hamartoma Tumor Syndrome",
        "Bannayan Riley Ruvalcaba Syndrome"
      ],
      "interventions": [
        {
          "name": "Everolimus blinded oral capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "5 Years to 45 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-09-01",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-11-03T06:25:23.777Z",
      "location_count": 3,
      "location_summary": "Stanford, California • Boston, Massachusetts • Cleveland, Ohio",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07218575"
    },
    {
      "nct_id": "NCT00549939",
      "title": "Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neurogenic Urinary Bladder"
      ],
      "interventions": [
        {
          "name": "Alfuzosin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 172,
      "start_date": "2007-10",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2014-10-29",
      "last_synced_at": "2026-11-03T06:25:23.777Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00549939"
    },
    {
      "nct_id": "NCT01406444",
      "title": "IGF-1 and Bone Loss in Women With Anorexia Nervosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anorexia Nervosa",
        "Osteopenia",
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "rhIGF-1",
          "type": "DRUG"
        },
        {
          "name": "Risedronate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 148,
      "start_date": "2011-10",
      "completion_date": "2019-05",
      "has_results": true,
      "last_update_posted_date": "2020-07-17",
      "last_synced_at": "2026-11-03T06:25:23.777Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01406444"
    },
    {
      "nct_id": "NCT01303744",
      "title": "Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "CHF 5074 1x",
          "type": "DRUG"
        },
        {
          "name": "CHF 5074 2x",
          "type": "DRUG"
        },
        {
          "name": "CHF 5074 3x",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CERESPIR",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 96,
      "start_date": "2011-03",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2016-01-11",
      "last_synced_at": "2026-11-03T06:25:23.777Z",
      "location_count": 5,
      "location_summary": "St. Petersburg, Florida • Eatontown, New Jersey • Monroe Twp, New Jersey + 2 more",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Eatontown",
          "state": "New Jersey"
        },
        {
          "city": "Monroe Twp",
          "state": "New Jersey"
        },
        {
          "city": "Toms River",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01303744"
    },
    {
      "nct_id": "NCT03022409",
      "title": "A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ceralasertib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 21,
      "start_date": "2017-09-18",
      "completion_date": "2021-01-20",
      "has_results": false,
      "last_update_posted_date": "2021-08-10",
      "last_synced_at": "2026-11-03T06:25:23.777Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03022409"
    },
    {
      "nct_id": "NCT00108849",
      "title": "Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Menopause",
        "Postmenopausal Vaginal Atrophy"
      ],
      "interventions": [
        {
          "name": "estradiol, 10 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 309,
      "start_date": "2005-03",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2017-02-08",
      "last_synced_at": "2026-11-03T06:25:23.777Z",
      "location_count": 51,
      "location_summary": "Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 45 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00108849"
    },
    {
      "nct_id": "NCT01524874",
      "title": "Comparative Effectiveness of Vitamin D and Repletion Strategies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypovitaminosis D",
        "Insulin Resistance",
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Vitamin D3",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Bastyr University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 66,
      "start_date": "2010-08",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2012-02-02",
      "last_synced_at": "2026-11-03T06:25:23.777Z",
      "location_count": 2,
      "location_summary": "Kailua-Kona, Hawaii • Kenmore, Washington",
      "locations": [
        {
          "city": "Kailua-Kona",
          "state": "Hawaii"
        },
        {
          "city": "Kenmore",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01524874"
    },
    {
      "nct_id": "NCT02087618",
      "title": "The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Kodro+",
          "type": "OTHER"
        },
        {
          "name": "Kodro+D",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Mt. Sinai Medical Center, Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2014-03",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2014-03-14",
      "last_synced_at": "2026-11-03T06:25:23.777Z",
      "location_count": 1,
      "location_summary": "Miami Beach, Florida",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02087618"
    }
  ]
}